Use of iron-based phosphate binders: A novel solution to an old problem

4^th International Conference on Nephrology & Therapeutics

September 14-16, 2015 Baltimore, USA

Mary M Bridgeman

The State University of New Jersey, USA

Posters-Accepted Abstracts: J Nephrol Ther

Abstract :

Chronic kidney disease (CKD) represents an enormous global public health concern, with an estimated 8-16% of the worldwide population affected by this condition. In the United States, more than 25 million Americans are estimated to have CKD. Hyperphosphatemia, a prevalent disorder of mineral metabolism in CKD patients, is a condition that may predispose patients to an increased risk of cardiovascular mortality related to uncontrolled hyperparathyroidism and vascular calcification. Controlling serum phosphate levels via use of dietary phosphate binders, along with dietary phosphate control, may help to reduce the adverse consequences of uncontrolled hyperphosphatemia. Phosphate binding agents work to reduce serum phosphate levels by forming an insoluble complex with dietary phosphorus in the gastrointestinal (GI) tract and allowing its elimination in the feces. Currently available phosphate binding agents include elemental compounds such as aluminum hydroxide, magnesium and calcium carbonate, calcium acetate, sucroferric oxyhydroxide, and lanthanum carbonate, and the nonelemental agent, sevelamer carbonate. In 2014, a novel iron-based dietary phosphate binder, ferric citrate, received approval from the United States Food and Drug Administration and the Japanese Ministry of Health for the treatment of hyperphosphatemia in patients with CKD on dialysis; consideration for approval by the European Medicines Agency is ongoing. A review of the safety and efficacy of this agent and other iron-based phosphate binders will be presented.

Biography :

Email: mary.bridgeman@pharmacy.rutgers.edu